Nested variant infiltrating bladder urothelial carcinoma
disease diseaseOn this page
Also known as infiltrating bladder urothelial carcinoma, nested variant
Summary
Nested variant infiltrating bladder urothelial carcinoma (MONDO:0004417) is a cancer and 1 clinical trial. Top therapeutic interventions include cisplatin and vinblastine. A subtype of infiltrating bladder urothelial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | nested variant infiltrating bladder urothelial carcinoma |
| Mondo ID | MONDO:0004417 |
| DOID | DOID:7969 |
| NCIT | C39819 |
| UMLS | C1512741 |
| MedGen | 268575 |
| GARD | 0023993 |
| Is cancer (heuristic) | yes |
Also known as: infiltrating bladder urothelial carcinoma, nested variant
Disease family
This is a subtype of infiltrating bladder urothelial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › bladder transitional cell carcinoma › infiltrating bladder urothelial carcinoma › nested variant infiltrating bladder urothelial carcinoma
Related subtypes (8): infiltrating bladder urothelial carcinoma, clear cell variant, micropapillary variant infiltrating bladder urothelial carcinoma, infiltrating bladder urothelial carcinoma sarcomatoid variant, infiltrating bladder lymphoepithelioma-like carcinoma, lipid-cell variant infiltrating bladder urothelial carcinoma, plasmacytoid variant infiltrating bladder urothelial carcinoma, microcystic variant infiltrating bladder urothelial carcinoma, lymphoma-like variant infiltrating bladder urothelial carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03912818 | PHASE2 | TERMINATED | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 1 |
| VINBLASTINE | 4 | 1 |
| CHEMBL4788494 | 0 | 1 |
Related Atlas pages
- Drugs: Cisplatin, Vinblastine